Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »
Weighing up STRENGTH – report and videos
Evinacumab in refractory hypercholesterolaemia
Novel PCSK9 therapies
13th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum
Keynote – Post CVD event depression: The prequel and sequel
Prof. David L. Hare presents an objective overview of the evidence for depression and cardiovascular disease, taking the following questions in turn. Does depression cause cardiovascular disease? And does cardiovascular disease cause depression?
Watch the webcast
Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”
Prof. Joseph L. Witztum overviews the evolving evidence for lipoprotein(a) as a cardiovascular risk factor, culminating in the Lp(a)HORIZON outcomes study. If positive, findings from this trial will have important public health implications.
Watch the webcast
Prof. Chris Packard, University of Glasgow, UK
Other related reports:
DA-VINCI: Need to do better with LDL cholesterol management in practice in Europe
The LDL frontier: what else do we need to know?
PCSK9 inhibition, low LDL cholesterol and lack of cognitive impairment: QED?